Skip to content

Jazz Pharmaceuticals JAZZ Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$23.44M-38.5%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount?
Jazz Pharmaceuticals (JAZZ) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount of -$49.98M in Q4 2025.
How has Jazz Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount changed year-over-year?
Jazz Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount decreased by 199.0% year-over-year, from $50.5M to -$49.98M.
What is the long-term trend for Jazz Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount has grown at a 25.2% compound annual growth rate (CAGR), from $81.28M to -$199.91M.
What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount mean?
The change in the reserve set aside for deferred tax assets that may not be realized.
How do you interpret effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount?
A decrease in the allowance (a benefit) suggests improved confidence in future profitability, while an increase suggests rising uncertainty regarding tax asset realization.
How does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount compare across companies?
Standard tax reconciliation item found in most corporate tax footnotes; highly dependent on specific jurisdictional tax laws.